UPDATE 2-Biohaven Pharma to continue late-stage study of Alzheimer's treatment
December 06, 2019 at 09:55 AM EST
Biohaven Pharmaceutical said on Friday it would continue testing its Alzheimer's disease treatment in a late-stage study as the drug had passed a so-called "futility analysis", sending shares up 4.1%.
